An open label, balanced, randomized, three-treatment, three-period, six-sequence, cross-over, single dose, comparative bioavailability pilot study of two test formulations of fixed dose combination capsules of acetylsalicylic acid (ASA) and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK comparing with AspirinĀ® Protect 100 mg tablets by Bayer vital GmbH, and ProtiumĀ® 20 mg gastro-resistant tablets by Nycomed GmbH, in healthy, adult, human subjects, under fasting conditions
acetylsalicylic acid/pantoprazole
Ulcers, Duodenal and Gastric
Phase 1
An analysis-ready dataset is not available for this study. An annotated case report form is not available for this study. A blank case report form will be provided.
May 2017